Grace Therapeutics, Inc. annual report, FY2023

Filing identity and business context

Important identification: The supplied filing is Acasti Pharma Inc.’s Form 10-K, not a filing by Grace Therapeutics, Inc. Grace is a wholly owned subsidiary acquired by Acasti in August 2021. Although the request labels the period “2022 Q4,” this is an annual report for the fiscal year ended March 31, 2023, comparing results with the year ended March 31, 2022. Financial figures below are in U.S. dollars; unless noted, amounts are in millions.

Acasti is a clinical-stage biopharmaceutical company developing reformulated drug candidates for rare and orphan diseases, with no product sales revenue. Following a strategic realignment announced in 2023, the company prioritized GTX-104, an intravenous nimodipine candidate for aneurysmal subarachnoid hemorrhage (aSAH), and deferred GTX-102 and GTX-101.

Financial results and liquidity

The larger net loss primarily reflects $28.682 million of intangible-asset impairment and $4.826 million of goodwill impairment, following the deferral of GTX-101 and GTX-102; these are non-cash charges. The impairment review also produced a $9.542 million income-tax recovery, including reversal of deferred tax liabilities. Operating expenses exclude any cost-of-sales or gross-margin measure because the company reported no product revenue. The filing reports no long-term debt; liabilities include payables, lease obligations and deferred taxes.

Operating cash use declined by $1.321 million year over year. Investing activities provided $13.153 million, mainly reflecting maturities of short-term investments; financing activities provided $0.304 million net from ATM share sales. Cash plus short-term investments fell from $43.661 million to $27.890 million. The filing states that cash resources were expected to fund operations into calendar Q2 2025 under the realignment plan, but that additional capital would be required beyond that period.

Material changes and developments

• R&D expense increased by $4.413 million, reflecting work across GTX-104, GTX-102 and GTX-101 before the strategic reprioritization. Acasti subsequently deferred further GTX-102 and GTX-101 development pending dedicated funding or partnerships.
• The company reported impairments of $22.712 million for GTX-102 and $5.970 million for GTX-101, plus $4.826 million of goodwill. GTX-104’s carrying value was not impaired in the review.
• In May 2023, Acasti announced a leaner U.S.-focused operating model, workforce reductions and a plan to discontinue Canadian operations over time. The filing reports $1.3 million of severance to be paid.
• Acasti voluntarily delisted from the TSX Venture Exchange effective March 27, 2023; its shares continued to trade on Nasdaq under ACST.
• In February 2023, Acasti dismissed KPMG and engaged Ernst & Young as auditor for FY2023. The filing reports no disagreements or reportable events with KPMG during the periods disclosed.

Outlook, risks and contingencies

• GTX-104: The FDA’s April 2023 feedback supported the proposed 505(b)(2) pathway and a planned Phase 3 safety study, subject to final protocol review and FDA approval. Acasti expected first-patient enrollment in the second half of 2023; the filing later reports submission of the full protocol and an expectation of first patient/first dose in calendar Q4 2023, pending FDA feedback. Management estimated the study would take about 18 months from first enrollment and expected it to be the final clinical step before seeking approval, subject to FDA requirements.
• Funding: The company has incurred recurring operating losses and negative operating cash flows and has no product-sales revenue. It expects to need additional financing; equity financing could dilute shareholders, and partnerships could require relinquishing rights. The $75 million ATM program was subject to SEC limitations, and the company sold 324,648 shares for gross proceeds of approximately $0.314 million during FY2023.
• Aker krill-oil supply dispute: Aker asserted a further $2.8 million was payable under a CaPre supply agreement. Acasti disputed the claim and recorded no liability. The dispute remained unresolved, and the filing says any required payment or product acceptance could cause a loss.
• Other risks: The business depends heavily on GTX-104, clinical and regulatory outcomes, third-party manufacturers and clinical service providers, and access to additional capital. The filing also identifies patent-litigation, commercialization, market-acceptance, reimbursement, foreign-exchange and Nasdaq-listing risks. Acasti had received a Nasdaq minimum-bid-price deficiency notice and an extension to July 24, 2023 to regain compliance.
• Tax: Acasti disclosed significant risk of being classified as a passive foreign investment company (PFIC) for U.S. tax purposes. It also reported U.S. and Canadian net operating losses, whose future use is subject to limitations and uncertainty.

Most important facts for investors to verify

1. Confirm the issuer and reporting period: this is Acasti Pharma Inc.’s FY2023 10-K, not Grace Therapeutics’ 2022 Q4 filing.
2. Check subsequent FDA decisions, protocol approval, enrollment and actual timing/results for GTX-104’s Phase 3 study.
3. Reassess cash runway against actual spending, financing proceeds and the company’s stated Q2 2025 runway estimate.
4. Track the unresolved Aker dispute and whether any liability, payment or inventory loss is ultimately recognized.
5. Review the assumptions underpinning the GTX-104 valuation and any further impairments; the auditor identified impairment testing of goodwill and acquired in-process R&D as a critical audit matter.
6. Verify Nasdaq listing compliance and subsequent financing, workforce and Canadian-operations transition costs.